Evotec (ETR:EVT) Stock Price Down 5% – What’s Next?

Evotec SE (ETR:EVT) dropped 5% on Friday . The stock traded as low as €5.31 and last traded at €5.40. Approximately 721,630 shares changed hands during trading, a decline of 47% from the average daily volume of 1,360,000 shares. The stock had previously closed at €5.69.

Evotec Trading Down 5.0%

The firm has a fifty day simple moving average of €5.06 and a two-hundred day simple moving average of €5.65. The firm has a market capitalization of $1.00 billion, a P/E ratio of -5.84, a price-to-earnings-growth ratio of 0.98 and a beta of 1.12. The company has a debt-to-equity ratio of 55.02, a current ratio of 2.07 and a quick ratio of 2.97.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.